Caribou Biosciences Reports $25.1 Million Net Loss in Q1 2026, Improved from $40 Million Loss in Q1 2025

Caribou Biosciences, Inc. reported a net loss of $25.1 million for the first quarter of 2026, a significant improvement compared to a net loss of $40.0 million during the same period in 2025. The company's revenue from licensing and other third-party agreements increased slightly to $2.4 million, up from $2.35 million year-over-year. Total operating expenses decreased to $28.7 million from $45.3 million, primarily due to a reduction in research and development costs, which fell to $20.6 million from $35.5 million. This reduction reflects strategic decisions to prioritize certain projects and a decrease in external costs associated with clinical trials.

In terms of financial position, Caribou's total assets decreased to $149.0 million as of March 31, 2026, down from $175.4 million at the end of 2025. The decline in assets was driven by a reduction in cash and cash equivalents, which stood at $12.1 million, compared to $12.4 million at the end of the previous year. The company also reported a decrease in total liabilities, which fell to $47.0 million from $53.2 million, largely due to a reduction in accrued expenses and other current liabilities.

Operationally, Caribou continues to advance its clinical-stage allogeneic CAR-T cell therapies, including vispacabtagene regedleucel (vispa-cel) and CB-011. The company is preparing for a pivotal phase 3 clinical trial for vispa-cel, which has received multiple designations from the FDA, including regenerative medicine advanced therapy (RMAT) and fast track designations. As of March 31, 2026, Caribou had 96.9 million shares outstanding, reflecting an increase from 95.1 million shares at the end of 2025, primarily due to stock option exercises and an at-the-market equity offering.

Looking ahead, Caribou expects to continue incurring substantial losses as it progresses its clinical trials and seeks regulatory approvals for its product candidates. The company anticipates that its existing cash, cash equivalents, and marketable securities, totaling $118.6 million, will be sufficient to fund operations for at least the next 12 months. However, management acknowledges the need for additional capital to support ongoing development and operational needs, emphasizing the importance of securing future financing to sustain its business strategy.